Home >> Industry News >> FDA authorizes BD combination COVID-19, flu rapid antigen test

FDA authorizes BD combination COVID-19, flu rapid antigen test

image_pdfCreate PDF

BD plans to launch the test this summer for the 2021–2022 flu season. The test is intended for individuals who are suspected by a health care provider of having COVID-19, flu A, or flu B within six days of symptom onset.

CAP TODAY
X